Sultan Waseem, Mathew Anup, Brown Matthew R D, Gálvez-Flórez Juan F, Moreno-Sanz Guillermo
Surrey and Borders Partnership NHS Foundation Trust, Leatherhead KT22 7AD, UK.
Zerenia Clinics, London SW1X 9AE, UK.
Brain Sci. 2022 Oct 29;12(11):1467. doi: 10.3390/brainsci12111467.
Emotionally unstable personality disorder (EUPD) is a common mental health disorder, manifesting with a range of chronic and debilitating symptoms, including impaired social functioning, unstable mood, and risky impulsive or self-injurious behaviour. Whilst the exact aetiology has not been fully elucidated, implicated factors seem to include genetic factors, environmental causes such as trauma, and neurotransmitter deficits. The literature suggests that impaired functioning of the endocannabinoid system in key brain regions responsible for emotional processing and stress response may underlie the manifestation of EUPD symptoms. The National Institute for Health and Care Excellence (NICE) 2009 guidelines state that "no drugs have established efficacy in treating or managing EUPD", and yet, patients are commonly prescribed medication which includes antipsychotics, antidepressants, and mood stabilisers. Here we present a case series of seven participants diagnosed with EUPD and treated with cannabis-based medicinal products (CBMPs). Participants were given an initial assessment and followed up one month after CBMPs prescription. Improvement in symptoms was assessed by the completion of ratified rating scales by the participant and psychiatrist. Our results indicate that CBMPs were effective and well tolerated, as six participants reported a noticeable improvement in their symptoms and functioning. Although promising, further research is needed to ascertain the long-term tolerability, efficacy, and dosing strategy for CBMPs in EUPD.
情绪不稳定人格障碍(EUPD)是一种常见的心理健康障碍,表现为一系列慢性且使人衰弱的症状,包括社交功能受损、情绪不稳定以及危险的冲动或自伤行为。虽然确切病因尚未完全阐明,但相关因素似乎包括遗传因素、诸如创伤等环境因素以及神经递质缺乏。文献表明,负责情绪处理和应激反应的关键脑区中内源性大麻素系统功能受损可能是EUPD症状表现的基础。英国国家卫生与临床优化研究所(NICE)2009年的指南指出,“尚无药物在治疗或管理EUPD方面具有已证实的疗效”,然而,患者通常会被开具包括抗精神病药、抗抑郁药和情绪稳定剂在内的药物。在此,我们呈现一个系列病例,涉及七名被诊断为EUPD并接受基于大麻的药用产品(CBMPs)治疗的参与者。参与者接受了初步评估,并在开具CBMPs处方一个月后进行了随访。通过参与者和精神科医生完成已批准的评定量表来评估症状改善情况。我们的结果表明,CBMPs有效且耐受性良好,因为六名参与者报告其症状和功能有明显改善。尽管前景乐观,但仍需要进一步研究以确定CBMPs在EUPD中的长期耐受性、疗效和给药策略。